Glycolysis is critical for cancer stem cell reprogramming; however, the underlying regulatory mechanisms remain elusive. Here, we show that pyruvate dehydrogenase kinase 1 (PDK1) is enriched in breast cancer stem cells (BCSCs), whereas depletion of PDK1 remarkably diminishes ALDH+ subpopulations, decreases stemness-related transcriptional factor expression, and inhibits sphere-formation ability and tumor growth. Conversely, high levels of PDK1 enhance BCSC properties and are correlated with poor overall survival. In mouse xenograft tumor, PDK1 is accumulated in hypoxic regions and activates glycolysis to promote stem-like traits. Moreover, through screening hypoxia-related lncRNAs in PDK1 positive tissue, we find that lncRNA H19 is responsible for glycolysis and BCSC maintenance. Furthermore, H19 knockdown decreases PDK1 expression in hypoxia, and ablation of PDK1 counteracts H19-mediated glycolysis and self-renewal ability in vitro and in vivo. Appropriately, H19 and PDK1 expression exhibits strong correlations in primary breast carcinomas. Importantly, H19 acting as a competitive endogenous RNA (ceRNA) sequesters miRNA let-7 to release HIF-1α, leading to an increase in PDK1 expression. Intriguingly, aspirin dramatically attenuates glycolysis and cancer stem-like characteristics by suppressing both H19 and PDK1. Collectively, these novel findings demonstrate that the glycolysis gatekeeper PDK1 plays a critical role in BCSC reprogramming and provides a potential therapeutic strategy for breast malignancy.